Eric Dube, Travere Therapeutics CEO

FDA punts Travere's rare kid­ney dis­ease NDA for three months, re­quest­ing REMS up­date

A for­mer Mar­tin Shkre­li biotech is at the FDA’s gates for its lead can­di­date, but it’s go­ing to have to wait a bit longer for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.